NEW YORK (AP) — More companies can make a nasal version of the opioid overdose antidote naloxone under a deal struck between New York's attorney general and the one company that sells it now.
The deal with Emergent BioSolutions opens the market, but it doesn't guarantee that more companies will offer the product.
The cost of Narcan has been a complication in the nation's opioid crisis. A New York investigation found that Emergent had a deal with a nasal spray device maker that restricted its products from being used with naloxone made by other companies.
